Comparative effects of carvedilol and metoprolol on cardiac ischemia- reperfusion injury

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 3, 1998, Pages 443-451

  Khandoudi, Nassirah ^a   Percevault Albadine, Joëlle ^a   Bril, Antoine ^a  

^a SmithKline Beecham Laboratoires P   (France)

Author keywords

Cardioprotection; Carvedilol; Ischemia reperfusion

Indexed keywords

CARVEDILOL; METOPROLOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PROTECTION; HEMODYNAMIC PARAMETERS; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; L-LACTATE DEHYDROGENASE; METOPROLOL; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PROPANOLAMINES; RABBITS; VENTRICULAR FUNCTION, LEFT;

EID: 0031706613     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199809000-00015     Document Type: Article

References (41)

1. Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR Jr. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens 1993;11(suppl 4):S41-8.
2. Yue TL, Liu T, Feuerstein GZ. Carvedilol, a new beta adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Res Commun 1992;1:27-35.
3. Lopez BL, Christopher TA, Yue T-L, Ruffolo RR Jr, Feuerstein GZ, Ma X-L. Carvedilol. a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 1995;51:165-73.
4. Ruffolo RR Jr, Boyle DA, Brooks DP, et al. Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovasc Drug Rev 1992;10:127-57.
5. Ma XL, Yue TL, Lopez BL, et al. Carvedilol, a new beta adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996;277:128-36.
6. Bril A, Slivjak MJ, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovasc Res 1992;26(5):518-25.
7. Hamburger SA, Barone FC, Feuerstein GZ, Ruffolo RR Jr. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 1991;43:113-20.
8. Feuerstein GZ, Hamburger SA, Smith III EF, Bril A, Ruffolo RR Jr. Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992;19:S138-41.
9. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8.
10. Raftery EB. The preventive effects of vasodilating beta-blockers in cardiovascular disease. Eur Heart J 1996;17:30-8.
11. Opie LH. The multifarious spectrum of ischemic left ventricular dysfunction: relevance of new ischemic syndromes. J Mol Cell Cardiol 1996;28:2403-14.
12. Scognamiglio R, Fasoli G, Nistri S, Marin M, Dalla Volta S. Left ventricular function and prognosis after myocardial infarction: rationale for therapeutics strategies. Cardiovasc Drugs Ther 1994;8:319-25.
13. Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic determinants of the time course of fall in canine left ventricular pressure. J Clin Invest 1976;58:751-8.
14. Serizawa T, Vogel WM, Apstein CS, Grossman W. Comparison of acute alterations in left ventricular diastolic chamber stiffness induced by hypoxia and ischemia. J Clin Invest 1981;68:91-102.
15. Feuerstein GZ, Poste G, Ruffolo RR Jr. Carvedilol update III: rationale for use in congestive heart failure. Drugs Today 1995;31:307-26.
16. Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure. Am Heart J 1996;131:337-41.
17. Saijonmaa O, Metsarinne K, Fyhrquist F. Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press 1997;6:24-8.
18. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
19. Yue TL, McKenna PJ, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new β-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992;214:277-80.
20. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 1995;294:585-91.
21. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The Precise Trial. Circulation 1996;94:2793-9.
22. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
23. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
24. Hearse DJ, Garlick PB, Humphrey SM. Ischemic contracture of the myocardium: mechanisms and prevention. Am J Cardiol 1977;39:986-93.
25. Paulus JP, Serizawa T, Grossman W. Altered left ventricular diastolic properties during pacing-induced ischemia in dogs with coronary stenosis. Circ Res 1982;50:218-27.
26. Nakaya H, Tohse N, Kanno M. Electrophysiological derangements induced by lipid peroxidation in cardiac tissue. Am J Physiol 1987;253:H1089-97.
27. Burton KP, Morris AC, Massey KD, Buja M, Hagler HK. Free radicals alter ionic calcium levels and membrane phospholipids in cultured rat ventricular myocytes. J Mol Cell Cardiol 1990;22:1035-47.
28. Eley DW, Korecky B, Fliss H, Desilets M. Calcium homeostasis in rabbit ventricular myocytes: disruption by hydrochlorous acid and restoration by dithiothreitol. Circ Res 1991;69:1132-8.
29. de Leiris J, Opie LH. Effect of substrates and of coronary artery ligation on mechanical performance and on release of lactate dehydrogenase and creatine phosphokinase in isolated working rat hearts. Cardiovasc Res 1978;12:585-96.
30. van Bilsen M, van der Vusse GJ, Willemsen PHM, et al. Lipid alterations in isolated, working rat hearts during ischemia and reperfusion: its relation to myocardial damage. Circ Res 1989;64:304-14.
31. Ruiz-Meana M, Garcia-Dorado D, Julia M, Gonzalez MA, Inserte J, Soler-Soler J. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovasc Res 1996;32:587-92.
32. Otani H, Prasad MR, Jones RM, Das DK. Mechanism of membrane phospholipid degradation in ischemia reperfused rat hearts. Am J Physiol 1989;257:H252-8.
33. Kramer JH, Mak IT, Weglicki WB. Differential sensitivity of canine cardiac sarcolemmal and microsomal enzymes to inhibition by free radical-induced lipid peroxidation. Circ Res 1984;55:120-4.
34. Mak IT, Arroyo CM, Weglicki WB. Inhibition of sarcolemmal carbon-centered free radical formation by propranolol. Circ Res 1989;65:1151-6.
35. Liu X, Engelman RM, Agrawal HR, Das DK. Preservation of membrane phospholipids by propranolol, pindolol, and metoprolol: a novel mechanism of action of beta-blockers. J Mol Cell Cardiol 1991;23:1091-100.
36. Riva E, Hearse DJ. Age-dependent changes in myocardial susceptibility to ischemic injury. Cardioscience 1993;4:85-92.
37. Cave AC, Horowitz GL, Apstein CS. Can ischemic preconditioning protect against hypoxia-induced damage? Studies of contractile function in isolated perfused rat hearts. J Mol Cell Cardiol 1994;26:1471-86.
38. Kolocassides KG, Seymour AML, Galinanes M, Hearse DJ. Paradoxical effect of ischemic contracture? NMR studies of energy metabolism and intracellular pH in the rat heart. J Mol Cell Cardiol 1996;28:1045-57.
39. Kolocassides KG, Galinanes M, Hearse DJ. Dichotomy of ischemic preconditioning. Circulation 1996;93:1725-33.
40. Lawson CS, Downey JM. Preconditioning: state of the art myocardial protection. Cardiovasc Res 1993;27:542-50.
41. Bril A, Tomasi V, Laville MP. Antiarrhythmic effect of carvedilol in rat isolated heart subjected to regional ischemia and reperfusion. Pharmacol Commun 1995;5:291-300.